Principle Investigator, NHLBI LAMPOON , intentional laceration of the anterior mitral leaflet to prevent left ventricular outflow tract obstruction during transcatheter mitral valve implantation.
Principle Investigator, Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis EARLY TAVR.
Principle Investigator, Transcatheter Mitral Valve Replacement with the Medtronic IntrepidTM TMVR System in patients with severe symptomatic mitral regurgitation – APOLLO Trial.
Principle Investigator, The Partner 3 Trial- Safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis.
Principal Investigator, Transcaval Aortic Valve Replacement Registry (NIH).
Principal Investigator, GALILEO: Comparing Rivaroxaban to antiplatelet based strategy after TAVR. (Bayer Healthcare).
Sub-Investigator, PHP Shield II: Cardiopulmonary support in complex PCI. (St. Jude Medical).
Sub-Investigator, THEMIS: Evaluating the effect of Ticagrelor vs. placebo on the incidence of CV Death, MI, or CVA in patients with T2DM (Astra Zeneca)(RAVE).
Sub-Investigator, TI-PAD: Ticagrelor vs. Aspirin in Ambulatory patients with PAD ABI <0.9(Astra Zeneca) (Datatrak).
Principle Investigator. PARACHUTE. Parachute Ventricular Restoration in Chronic Heart Failure due to Ischemic Heart Disease (Cardio Kinetix Inc).
Sub-Investigator, TIMI 61 CAMELLIA. Evaluating the safety and efficacy of Lorcaserin (Belviq) a weight loss drug in patients at high-risk for cardiovascular events (Eisai).
Sub-Investigator, PRADAXA GI. Evaluating the gastrointestinal symptoms of patients when taking Pradaxa with food or pantoprazole (Protonix) vs. an empty stomach. (Boehringer Ingelheim).
Principal Investigator, DECLARE—TIMI 58. To Evaluate the effect of Dapagliflozin on Cardiovasclar Events ( Astra Zeneca and Bristol Myers Squibb).
Principal Investigator, ODYSSEY. To evaluate the effectiveness of an antibody to impair PCSK9 function resulting in lower LDL. Sanofi and DCRI.
Sub-Investigator, EXCEL, The evaluation of Xience Prime or Xience 4 versus Coronary Artery Bypass Surgery for effectiveness of left main revascularization. Sponsor: Abbott.
Co-Investigator, ABSORB BVS, The Everolimus Eluting Bioresorbable vascular scaffold in the treatment of subjects with De Novo native coronary artery lesions. Sponsor: Abbott.
Sub-Investigator, PIONEER AF-PCI. Treatment Strategies with Rivaroxaban (Xeralto) vs. Warfarin in patients with AF who undergo PCI (Janssen).
Sub-investigator, ENDEAVOR, A clinical evaluation of the Zotarolimus-Eluting Coronary stent system in the treatment of De Novo lesions in native coronary arteries with a reference vessel diameter of 2.25mm to 4.2mm. Sponsor: Medtronic.
Sub-Investigator, COREVALVE, To evaluate the safety and efficacy of the Medtronic CoreValve System in the treatment of symptomatic severe aotic stenosis in subjects who have a predicted high risk for aortic valve surgery. Sponsor: Medtronic.
Sub-Investigator, EUCLID Sponsor: AstraZeneca and DCRI. Comparing ticagrelor with clopidogrel tt on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established PAD.
Sub-Investigator, CIRT. NIH Cardiovascular Inflammation Reduction Trial using low-dose methotrexate (LDM) in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with type 2 diabetes.
Sub-Investigator, “Accent MRI pacemaker and Tendril MRI Lead IDE Study” – St. Jude Medical.
Principal Investigator, EXAMINE. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome. Takeda.
Sub-Investigator, REDUCE-IT. To Evalulate the effect of AMR101 on Cardiovascular health and Mortality in Hypertriglyceridemic patients with CV disease or at High Risk for CV disease. Amarin.
Sub-Investigator, REVEAL—TIMI 55. To determine the clinical effects of anacetrapib among people with established vascular disease. Merck/ Brigham and Women’s Hospital/University of Oxford.
Principal Investigator, ALERTS, for Early Recognition of STEMI. Angel Medical Guardian System.
Sub-Investigator, Astra Zeneca PEGASUS – TIMI 54. Evaluation of long-term efficacy and safety of Ticagrelor in patients with history of Myocardial Infarction from one to three years prior to enrollment. Astra Zeneca and the TIMI Study Group.
Principal Investigator, SAVOR-TIMI 53 –“Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus’. Astra Zeneca and the TIMI Study Group.
Sub-investigator, TRILOGY “A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) subjects with Unstable Angina(UA)/Non-ST-elevated Myocardial Infarction (NSTEMI) who are medically managed. Eli Lilly and Duke Clinical Research Institute.
Sub-investigator DAL-OUTCOMES “To evaluate the effects of dalcetrapib on CV risk in stable CHD patients with a documented recent Acute Coronary Syndrome”. Roche and Mayo Clinic.
Sub-investigator, TRA2P-TIMI 50 – ‘Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events’. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease. Schering Plough and the Timi Study Group.
Sub-investigator, APPRAISE 2- “Apixaban for Prevention of Acute ischemic Events.’ A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban n Subjects with a Recent Acute Coronary Syndrome. Brisol-Myers-Squibb and Duke Clinical Research Institute.
Sub-investigator Sanofi Aventis SEPIA/ACS (TIMI 42/A) A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in patients with non-ST elevation acute coronary syndrome and planned early invasive strategy-Phase 2B at Inova Fairfax Hospital.
Sub-investigator, The ENDEAVOR IV Trial: A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesion, Inova Fairfax Hospital.
Sub-investigator, ACUITY trial, A randomized comparison of Angiomax® (bivalirudin) versus heparin (enoxaparin or unfractionated heparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation-(Phase IV) at Inova Fairfax Hospital.
Sub-investigator, SYNERGY, A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndrome (ACS) (Phase IV), Inova Fairfax Hospital.